Market Place
Sourcing Support
EMA committee recommends approval for CStone Pharma’s Cejemly in combo
05 Jun 2024 //
PHARMABIZ
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
03 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
EMA CHMP Recommends Cejemly Approval As 1L NSCLC Treatment
01 Jun 2024 //
PR NEWSWIRE
CStone gets a win for sugemalimab in oesophageal cancer
03 Jan 2023 //
PHARMAPHORUM
EQRx receives MHRA marketing approval for sugemalimab
21 Dec 2022 //
PHARMATIMES
For its two medicines, EQRx abandons its bold strategy to lower drug prices
11 Nov 2022 //
STATNEWS
EQRx announces further results from phase 3 trial of sugemalimab
08 Aug 2022 //
PHARMATIMES
CStone presents updated results of a registrational study of sugemalimab
07 Aug 2022 //
PRNEWSWIRE
Pfizer PD-L1 partner explores sale: Bloomberg
14 Jul 2022 //
FIERCEPHARMA
CStone and Pfizer announce NMPA approval of sugemalimab in NSCLC
06 Jun 2022 //
ASIAONE
CStone says GEMSTONE-302 study of sugemalimab met endpoint of overall survival
18 Jan 2022 //
PRNEWSWIRE
CStone completes enrollment in two key phase 3 trials of sugemalimab
18 Jan 2022 //
ASIAONE
CStone announces the clinical data from registrational study of Sugemalimab
14 Jan 2022 //
ASIAONE
CStone Pharmaceuticals Receives Approval in China for Sugemalimab
22 Dec 2021 //
BUSINESSWIRE
CStone Announced New Drug Approval Of Cejemly (Sugemalimab)
21 Dec 2021 //
BIOSPACE
CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY IN CHINA
21 Dec 2021 //
PRNEWSWIRE
EQRx Presents PIII Data for Sugemalimab with Chemotherapy in Stage IV NSCLC
13 Sep 2021 //
BUSINESSWIRE
NMPA accepts CStone’s NDA for sugemalimab to treat unresectable stage III NSCLC
04 Sep 2021 //
PHARMABIZ
CStone announces the results of GEMSTONE-302, Sugemalimab
23 Nov 2020 //
FIRSTWORLDPHARMA
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint
26 Oct 2020 //
PRNEWSWIRE
Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in China
30 Sep 2020 //
PHARMAPHORUM
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs
29 Sep 2020 //
BUSINESSWIRE
First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combo
16 Apr 2019 //
PR NEWSWIRE
Innovative Biotech Company CStone Pharmaceuticals Receives $150m in Series A
04 Jul 2016 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.